Investor
Relations

We are committed to developing transformational biologic medicines to serve patients with debilitating diseases

Presentations

Date	Title
Mar 09, 2023	AMT Corporate Presentation March 2023
Jul 25, 2022	MARKET Phase 2 Combination Data
Apr 25, 2022	FILLMORE Chronic Pouchitis Phase 2 Top line Data
Oct 15, 2021	AMT Research & Development Day Presentation